The logo of Swiss drugmaker Roche at its headquarters in Basel, Switzerland, on Jan. 30, 2020. (Arnd Wiegmann/Reuters)
ZURICH—Swiss drugs regulator Swissmedic said on Monday it approved Ronapreve, an antibody treatment jointly developed by Roche and Regeneron, to treat COVID-19 patients.
“In this procedure, no data on efficacy against the Omicron variant were submitted,” Swissmedic said in a statement.
The antibody treatment was already authorized for prescription in Switzerland under COVID-19 Ordinance 3 since April 15, Swissmedic said.